2. Search Result
Search Result
Results for "

dry+eye

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

2

Natural
Products

3

Isotope-Labeled Compounds

2

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19344
    Lifitegrast
    Maximum Cited Publications
    11 Publications Verification

    SAR 1118; SHP-606

    		 Integrin Inflammation/Immunology
    Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast
  • HY-B1893
    Fluorometholone
    2 Publications Verification

    		 Glucocorticoid Receptor Inflammation/Immunology
    Fluorometholone, a synthetic glucocorticoid, is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic properties. Fluorometholone can be used for the research of dry eye .
    Fluorometholone
  • HY-B0606
    Diquafosol tetrasodium
    5 Publications Verification

    INS365

    		 P2Y Receptor Inflammation/Immunology
    Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.
    Diquafosol tetrasodium
  • HY-19344A
    Lifitegrast sodium
    Maximum Cited Publications
    11 Publications Verification

    SAR 1118 sodium; SHP-606 sodium

    		 Integrin Inflammation/Immunology
    Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .
    Lifitegrast sodium
  • HY-107150
    Reproxalap

    ADX-102; NS-2

    		 PKC Caspase Neurological Disease Inflammation/Immunology
    Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis .
    Reproxalap
  • HY-172435
    Rezuforimod

    AGN-232411; AG-80308; AGN-411

    		 Formyl Peptide Receptor (FPR) Neurological Disease
    Rezuforimod (AGN-232411; AG-80308) is an ophthalmic solution targeting the formyl peptide receptor (FPR) pathway. Rezuforimod exerts anti-inflammatory effects by targeting the formyl peptide receptor pathway. Administered topically, Rezuforimod significantly reduces the corneal conjunctival staining score and improves ocular discomfort symptoms, with no serious adverse events reported and favorable overall safety profile. Rezuforimod shows remarkable potential to serve as a novel therapeutic option for dry eye disease .
    Rezuforimod
  • HY-132596A
    Tivanisiran sodium

    SYL1001 sodium

    		 Small Interfering RNA (siRNA) TRP Channel Neurological Disease
    Tivanisiran sodium (SYL1001 sodium) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran sodium induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran sodium alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran sodium is applicable to research related to dry eye disease .
    Tivanisiran sodium
  • HY-106449
    Recoflavone

    DA-6034 free acid

    		 NF-κB COX Apoptosis ERK Calcium Channel Inflammation/Immunology Cancer
    Recoflavone (DA-6034 (free acid)), a synthetic derivative of the flavonoid Eupatilin (HY-N0783), is orally active. Recoflavone can inhibit the NF-κB pathway and induce [Ca( 2+)]i increase in epithelial cells. Recoflavone exhibits activities such as anti-inflammation, anti-tumor effects, protection of gastric and intestinal mucosa, and promotion of secretion in the ocular surface and salivary glands. Recoflavone can be used for the research of diseases such as dry eye, gastric injury, and intestinal injury .
    Recoflavone
  • HY-W143531
    Perfluorohexyloctane

    NOV03; SHR8058

    		 Biochemical Assay Reagents Inflammation/Immunology
    Perfluorohexyloctane (NOV03), a semifluorinated alkane, reduces tear film instability in Meibomian gland dysfunction and evaporative dry eye disease. Perfluorohexyloctane is a long-term tamponade agent. Perfluorohexyloctane increases tear film breakup time and lipid layer thickness .
    Perfluorohexyloctane
  • HY-P10904
    Vezocolmitide

    ST-100

    		 Collagen Others
    Vezocolmitide (ST-100) is a collagen mimetic peptide. Vezocolmitide can rapidly repair damaged collagen triple helix structures, thereby quickly reversing damage to the ocular surface and extracellular matrix, and restoring corneal nerve function while repairing the epithelium. Vezocolmitide can be used for research of dry eye disease (DED) .
    Vezocolmitide
  • HY-W010708
    Cholesteryl palmitate

    		Endogenous Metabolite Inflammation/Immunology
    Cholesteryl palmitate is the main cholesterol ester found in human blephariol and has been used to form a stable tear film to study amphiphilic block copolymers as surfactants for dry eye syndrome. Cholesteryl palmitate can be used as a predictor of fetal lung maturity. Cholesteryl palmitate can be used as a prognostic biomarker for chronic interstitial pneumonia .
    Cholesteryl palmitate
  • HY-152264
    CFTR activator 1

    		CFTR Inflammation/Immunology
    CFTR activator 1 is a potent and selective CFTR activator, with an EC50 of 23 nM. CFTR activator 1 can be used to ameliorate dry eye disease .
    CFTR activator 1
  • HY-P11273
    Urcosimod

    OK 101

    		 Chemerin Receptor Neurological Disease Inflammation/Immunology
    Urcosimod (OK 101) is a lipid-coupled chemokine peptide, a ChemR23 G protein-coupled receptor agonist, which has been shown to have anti-inflammatory and analgesic activities. Urcosimod can be used for dry eye research .
    Urcosimod
  • HY-17639
    Navamepent

    RX-10045

    		 Biochemical Assay Reagents Inflammation/Immunology
    Navamepent is an analog of naturally occurring resolvin E1 (a major dietary omega-3 polyunsaturated fatty-acid metabolite) with potent anti-inflammatory and cell survival benefits. Navamepent is highly effective against dry eye and goblet cell loss thereby accelerating tear production. Also, Navamepent can reduce corneal inflammation, epithelial damage, and accelerate corneal tissue repair. In addition, Navamepent can inhibit the release of several key proinflammatory mediators from corneal epithelial cells. Navamepent is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Navamepent
  • HY-B0633O
    Hyaluronic acid sodium (MW 5000)

    		Endogenous Metabolite Bacterial Neurological Disease
    Hyaluronic acid (sodium) (MW 5000) is a biopolymer composed of repeating disaccharide units with a molecular weight of 5000. Hyaluronic acid (sodium) (MW 5000) can be used for dry-eye syndrome research .
    Hyaluronic acid sodium (MW 5000)
  • HY-B2206
    Gefarnate

    		Mucin Inflammation/Immunology
    Gefarnate is a agent used for the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of dry eye syndrome.
    Gefarnate
  • HY-132596
    Tivanisiran

    SYL1001

    		 Small Interfering RNA (siRNA) TRP Channel Neurological Disease
    Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA .
    Tivanisiran
  • HY-P99578
    Tanfanercept

    HL036337; HBM9036

    		 TNF Receptor Inflammation/Immunology
    Tanfanercept (HL036337) is an TNF-α receptor fusion protein that targets TNF-α. Tanfanercept is effective in ameliorating corneal erosions in a dry eye (DE) mouse model .
    Tanfanercept
  • HY-169675
    Lacripep

    		Endogenous Metabolite Neurological Disease Endocrinology
    Lacripep is a synthetic tear protein. Lacripep binds to and activates syndecan-1 (SDC1). Lacripep restores progenitor cell identity and epithelial barrier function. Lacripep resolves dry eye .
    Lacripep
  • HY-B1893R
    Fluorometholone (Standard)
    2 Publications Verification

    		 Reference Standards Glucocorticoid Receptor Inflammation/Immunology
    Fluorometholone (Standard) is the analytical standard of Fluorometholone. This product is intended for research and analytical applications. Fluorometholone, a synthetic glucocorticoid, is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic properties. Fluorometholone can be used for the research of dry eye .
    Fluorometholone (Standard)
  • HY-151611
    UAMC-00050

    		Ser/Thr Protease Inflammation/Immunology
    UAMC-00050 is a potent trypsin-like serine protease inhibitor. UAMC-00050 can be used in research of dry eye syndrome and ocular inflammation .
    UAMC-00050
  • HY-19344R
    Lifitegrast (Standard)

    SAR 1118 (Standard); SHP-606 (Standard)

    		 Reference Standards Integrin Inflammation/Immunology
    Lifitegrast (Standard) is the analytical standard of Lifitegrast. This product is intended for research and analytical applications. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast (Standard)
  • HY-153567
    Immune cell migration-IN-2

    		Biochemical Assay Reagents Inflammation/Immunology
    Immune cell migration-IN-2 is a potent immune cell migration inhibitor with an EC50 of 13.5 nM in a T-cell adhesion assay. Immune cell migration-IN-2 is extracted from patent WO2019001171, example 11, can be used for dry-eye and other retinal diseases research . Immune cell migration-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Immune cell migration-IN-2
  • HY-B0606A
    Diquafosol

    INS365 free base

    		 Apoptosis P2Y Receptor Reactive Oxygen Species (ROS) Inflammation/Immunology
    Diquafosol (INS365 free base) is a potent P2Y2 agonist. Diquafosol nhibits apoptosis and decreases ROS generation. Diquafosol has the potential for the research of dry eye .
    Diquafosol
  • HY-153565
    Immune cell migration-IN-1

    		Others Inflammation/Immunology
    Immune cell migration-IN-1 (compound 2) is a potent agent to inhibit immune cell migration. Immune cell migration-IN-1 can be used for research in alleviating dry eye diseases, eczema dermatitis and psoriasis .
    Immune cell migration-IN-1
  • HY-154994
    JAK-IN-30

    		JAK Inflammation/Immunology
    JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED) .
    JAK-IN-30
  • HY-U00277
    JAK-IN-10

    		JAK Inflammation/Immunology
    JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders . JAK-IN-10 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    JAK-IN-10
  • HY-W010708R
    Cholesteryl palmitate (Standard)

    		Reference Standards Endogenous Metabolite Inflammation/Immunology
    Cholesteryl palmitate (Standard) is the analytical standard of Cholesteryl palmitate. This product is intended for research and analytical applications. Cholesteryl palmitate is the main cholesterol ester found in human blephariol and has been used to form a stable tear film to study amphiphilic block copolymers as surfactants for dry eye syndrome. Cholesteryl palmitate can be used as a predictor of fetal lung maturity. Cholesteryl palmitate can be used as a prognostic biomarker for chronic interstitial pneumonia.
    Cholesteryl palmitate (Standard)
  • HY-19344S2
    Lifitegrast-d4-1

    		Isotope-Labeled Compounds Integrin Inflammation/Immunology
    Lifitegrast-d4-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast-d4-1
  • HY-151611A
    UAMC-00050 free base

    		Ser/Thr Protease Neurological Disease Inflammation/Immunology
    UAMC-00050 free base is a potent trypsin-like serine protease inhibitor. UAMC-00050 free base can be used in research of dry eye syndrome and ocular inflammation .
    UAMC-00050 free base
  • HY-171925
    BI-1124

    		Cathepsin Neurological Disease
    BI-1124 is a cathepsin S inhibitor that exhibits simulated sufficient ocular pharmacokinetic-pharmacodynamic coverage in rabbit models via topical ocular administration. BI-1124 can be used for the research of age-related dry eye disease .
    BI-1124
  • HY-125500
    TOP1362

    		p38 MAPK Syk Src Neurological Disease
    TOP1362 is a narrow spectrum kinase inhibitor. TOP1362 is a potent inhibitor of P38-α and Syk kinases with Kd values of 26 and 18 nM, respectively and an IC50 of 14 nM in the Src kinase activity assay. TOP1362 potently inhibits P38-α, Src and Syk. TOP1362 can be used in the research of dry eye syndrome .
    TOP1362
  • HY-180939
    LFA-1-IN-2

    		Integrin Neurological Disease Inflammation/Immunology
    LFA-1-IN-2 (Compound 25) is a potent LFA-1 inhibitor with a Kd of 21.46 μM. LFA-1-IN-2 inhibits ICAM-1-mediated cell adhesion. LFA-1-IN-2 protects cells from inflammatory hyperosmotic stress. LFA-1-IN-2 improves dry eye disease .
    LFA-1-IN-2
  • HY-19344S
    Lifitegrast-d4

    SAR 1118-d4; SHP-606-d4

    		 Isotope-Labeled Compounds Inflammation/Immunology
    Lifitegrast-d4 (SAR 1118-d4) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast-d4
  • HY-19344S1
    Lifitegrast-d6

    SAR 1118-d6; SHP-606-d6

    		 Isotope-Labeled Compounds Inflammation/Immunology
    Lifitegrast-d6 (SAR 1118-d6) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast-d6
  • HY-107150R
    Reproxalap (Standard)

    ADX-102 (Standard); NS-2 (Standard)

    		 Reference Standards PKC Caspase Neurological Disease Inflammation/Immunology
    Reproxalap (Standard) (ADX-102 (Standard)) is the analytical standard of Reproxalap (HY-107150). This product is intended for research and analytical applications. Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis .
    Reproxalap (Standard)
  • HY-106449R
    Recoflavone (Standard)

    DA-6034 free acid (Standard)

    		 Reference Standards NF-κB COX Apoptosis ERK Calcium Channel Inflammation/Immunology Cancer
    Recoflavone (Standard) is the analytical standard of Recoflavone (HY-106449). This product is intended for research and analytical applications. Recoflavone (DA-6034 (free acid)), a synthetic derivative of the flavonoid Eupatilin (HY-N0783), is orally active. Recoflavone can inhibit the NF-κB pathway and induce [Ca(2+)]i increase in epithelial cells. Recoflavone exhibits activities such as anti-inflammation, anti-tumor effects, protection of gastric and intestinal mucosa, and promotion of secretion in the ocular surface and salivary glands. Recoflavone can be used for the research of diseases such as dry eye, gastric injury, and intestinal injury .
    Recoflavone (Standard)
  • HY-171216
    GW559090

    		Integrin Neurological Disease
    GW559090 is a selective, competitive, and high-affinity α4 integrin antagonist with a Kd of 0.19 nM for α4β1. GW559090 can effectively block the binding of α4β1 to vascular cell adhesion molecule 1 (VCAM-1) and fibronectin with IC50 values of 7.72 and 8.04 nM. GW559090 also inhibits the interaction between α4β7 and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) (IC50 = 23 nM). GW559090 can inhibit inflammatory infiltration in the eyes, repair the corneal barrier and restore the function of goblet cells. GW559090 can be used for research of Sjögren's syndrome associated dry eye .
    GW559090
  • HY-183905
    KR-67607

    		11β-HSD Glucocorticoid Receptor Reactive Oxygen Species (ROS) Keap1-Nrf2 Neurological Disease
    KR-67607 is a selective 11β-HSD1 inhibitor, with an IC50 value of 4.8 nM against h11β-HSD1 and 7.1 nM against mouse 11β-HSD1. KR-67607 inhibits stress-induced Glucocorticoid receptor nuclear translocation, reduces cortisol levels, suppresses the expression of ROS and proinflammatory cytokines, and enhances Nrf-2-mediated antioxidant gene transcription. KR-67607 maintains trabecular meshwork structure and reverses elevated intraocular pressure. KR-67607 improves ocular antioxidant activity and mucus secretion, reverses ocular surface damage, and prevents ischemia-reperfusion induced ocular injury. KR-67607 can be used in research related to glaucoma and dry eye disease .
    KR-67607

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: